ClinicalTrials.gg
CompletedNCT02390687Updated Jan 10, 2017

Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients

A Phase 3 interventional study of Probiotic and Placebo in Chronic Periodontitis, sponsored by Next Gen Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 35 Years to 49 Years. Per ClinicalTrials.gov, last updated 2017-01-10.

Sponsored by Next Gen Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
35 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Chronic Periodontitis with a site in India — 2 open to participants now, 3 under way, none of them phase 3. Chronic Periodontitis · India.

Enrollment
34th of 46
31 · median 53
Started
2015
with 11 others
Phase 3
8 of 53
none open now
Registered
16th of 53
by date
Lead sponsor
2 of 53
Next Gen Pharma India Pvt. Ltd.

Among the 53 studies in Chronic Periodontitis with a site in India, this one is the 34th largest by enrollment of the 46 interventional ones that give a count, is one of 12 that started in 2015, is one of 8 in phase 3, and was the 16th registered.

Chronic Periodontitis

377 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

Browse Chronic Periodontitis studies →

Open to participants now

2 of the 53 studies in Chronic Periodontitis with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 35 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Chronic Periodontitis with a site in India, or all of them as a file.
02

Study summary

Periodontitis is an infectious inflammatory disease. Bacteria modulate the inflammatory response and alter the diversity of periodontal disease. In recent years, various host-response modulation therapies have been developed to block the pathways responsible for periodontal tissue breakdown.

There have been significant changes with respect to the effectiveness of, and attitudes towards conventional antimicrobial therapy to combat disease. With the threat of widespread antibiotic resistance rendering many antibiotics useless against important diseases, there is an increased necessity not only to minimise antibiotic use and develop novel non-antibiotic-based treatments, but also to raise the profile of disease prevention. One approach that has gained interest over recent years is the use of probiotic bacteria for oral applications. The rationale for their use in oral health care stems from the increase in evidence that supports their claims for benefit for a range of diseases. Lactobacilli play an important role in the maintenance of health by stimulating the natural immunity as well as by contributing to the balance of the microflora, by interacting with the other members of the flora. The application of health promoting bacteria for therapeutic purposes, is one of the strongest emerging fields. Time has come to shift the paradigm of the treatment from specific bacteria elimination to alteration of the bacterial ecology by using probiotics.

So the purpose of this study is to discover a more promising approach for the treatment of chronic periodontitis .

03

Conditions studied

  • Chronic Periodontitis

Browse trials for

04

Who can participate

Ages eligible
35 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically diagnosed chronic generalized periodontitis
  • Need of phase 1 therapy
  • Pocket probing depth (PPD) of ≥ 5 mm \< 7 mm at two and/or more sites
  • Patients with no history of allergies to the drugs to be used

Exclusion criteria

Exclusion Criteria:

  • Patients on antibiotics within 3 month prior to study
  • Patients with any systemic diseases
  • Patients with history of any periodontal therapy within 6 months to trial
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Placebo comparator
    Placebo Arm

    Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

    Drug: Placebo

  • Experimental
    Probiotic Arm

    L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2

    Drug: Probiotic

Interventions

  • Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2

    Also known as: L. brevis CD2 Lozenges

  • DrugPlacebo

    Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

06

What researchers measure

Primary outcomes

  1. Improvement in Periodontal Clinical indices

    Improvement in periodontal clinical indices, namely, Gingival Index (GI), Bleeding on probing (BOP), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).

    Time frame: 8 weeks

Secondary outcomes

  1. Change in bone pattern

    Assessment of changes in bone patterns in bith group using digital radio-graphic technique

    Time frame: 8 weeks

07

Study locations

1 site
  • Department of Periodontics, K.V.G. College & Hospital,
    Kurunjibhag, Sullia (D.K.), Karnataka 574327, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2015
First posted
Mar 17, 2015
Start
Apr 2015
Primary completionActual
Sep 2016
CompletionActual
Dec 2016
Last update
Jan 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02390687
Lead sponsor
Next Gen Pharma India Pvt. Ltd.
Collaborators
KVG Medical College and Hospital
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Apr 2015
Primary completion
Sep 2016
Completion
Dec 2016
Last update
Jan 10, 2017

Study contacts

Mudnoor M Dayakar, MDS
principal investigator · KVG Medical College & Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion